Valbiotis - Combined Shareholders General Meeting Held on May 5, 2022
06 Mai 2022 - 05:40PM
Business Wire
Regulatory News:
Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, PEA / PME
eligible), a Research and Development company committed to
scientific innovation for preventing and combating metabolic
diseases, announces its Combined Shareholders Meeting was held on
May 5, 2022 at Espace Encan, La Rochelle, under the chairmanship of
Sébastien PELTIER, Chairman of the Board of Directors, and that all
the resolutions submitted for voting have been adopted by its
shareholders.
All information related to this Shareholders’ Meeting is
available at: https://www.valbiotis.com/en/general-assemblies/
About Valbiotis
Valbiotis is a Research & Development company committed to
scientific innovation for preventing and combating metabolic and
cardiovascular diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to
revolutionize healthcare by developing a new class of health
nutrition products designed to reduce the risk of major metabolic
diseases, relying on a multi-target strategy enabled by the use of
plant-based terrestrial and marine resources.
Its products are intended to be licensed to players in the
health sector.
Created at the beginning of 2014 in La Rochelle, the Company has
forged numerous partnerships with leading academic centers. The
Company has established three sites in France – Périgny, La
Rochelle (17) and Riom (63) – and a subsidiary in Quebec City
(Canada).
Valbiotis is a member of the "BPI Excellence" network and has
been recognized as an "Innovative Company" by the BPI label.
Valbiotis has also been awarded "Young Innovative Company" status
and has received major financial support from the European Union
for its research programs via the European Regional Development
Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit:
www.valbiotis.com
Name: Valbiotis ISIN code: FR0013254851 Mnemonic code: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about
Valbiotis’ objectives. Valbiotis considers that these projections
are based on rational hypotheses and the information available to
Valbiotis at the present time. However, in no way does this
constitute a guarantee of future performance, and these projections
may be affected by changes in economic conditions and financial
markets, as well as certain risks and uncertainties, including
those described in the Valbiotis Universal Registration Document
approved by the French Financial Markets Regulator (AMF) on July
27, 2021 (application number R 21-039). This document is available
on the Company’s website (www.valbiotis.com). This press release
and the information it contains do not constitute an offer to sell
or subscribe, or a solicitation to purchase or subscribe to
Valbiotis’ shares or financial securities in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220506005307/en/
Corporate communication / Valbiotis Carole ROCHER / Marc
DELAUNAY +33 5 46 28 62 58 media@valbiotis.com
Financial communiation / Actifin Stéphane RUIZ +33 1 56 88 11 14
sruiz@actifin.fr
Valbiotis (EU:ALVAL)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Valbiotis (EU:ALVAL)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024